Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Jul;24(36):1–152. doi: 10.3310/hta24360

Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study.

Ashley P Jones, Dannii Clayton, Gloria Nkhoma, Frances C Sherratt, Matthew Peak, Simon R Stones, Louise Roper, Bridget Young, Flora McErlane, Tracy Moitt, Athimalaipet V Ramanan, Helen E Foster, Paula R Williamson, Samundeeswari Deepak, Michael W Beresford, Eileen M Baildam
PMCID: PMC7443738  PMID: 32758350

Abstract

BACKGROUND

In the UK, juvenile idiopathic arthritis is the most common inflammatory disorder in childhood, affecting 10 : 100,000 children and young people aged < 16 years each year, with a population prevalence of around 1 : 1000. Corticosteroids are commonly used to treat juvenile idiopathic arthritis; however, there is currently a lack of consensus as to which corticosteroid induction regimen should be used with various disease subtypes and severities of juvenile idiopathic arthritis.

OBJECTIVE

The main study objective was to determine the feasibility of conducting a randomised controlled trial to compare the different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis.

DESIGN

This was a mixed-methods study. Work packages included a literature review; qualitative interviews with children and young people with juvenile idiopathic arthritis and their families; a questionnaire survey and screening log to establish current UK practice; a consensus meeting with health-care professionals, children and young people with juvenile idiopathic arthritis, and their families to establish the primary outcome; a feasibility study to pilot data capture and to collect data for future sample size calculations; and a final consensus meeting to establish the final protocol.

SETTING

The setting was rheumatology clinics across the UK.

PARTICIPANTS

Children, young people and their families who attended clinics and health-care professionals took part in this mixed-methods study.

INTERVENTIONS

This study observed methods of prescribing corticosteroids across the UK.

MAIN OUTCOME MEASURES

The main study outcomes were the acceptability of a future trial for children, young people, their families and health-care professionals, and the feasibility of delivering such a trial.

RESULTS

Qualitative interviews identified differences in the views of children, young people and their families on a randomised controlled trial and potential barriers to recruitment. A total of 297 participants were screened from 13 centres in just less than 6 months. In practice, all routes of corticosteroid administration were used, and in all subtypes of juvenile idiopathic arthritis. Intra-articular corticosteroid injection was the most common treatment. The questionnaire surveys showed the varying clinical practice across the UK, but established intra-articular corticosteroids as the treatment control for a future trial. The primary outcome of choice for children, young people, their families and health-care professionals was the Juvenile Arthritis Disease Activity Score, 71-joint count. However, results from the feasibility study showed that, owing to missing blood test data, the clinical Juvenile Arthritis Disease Activity Score should be used. The Juvenile Arthritis Disease Activity Score, 71-joint count, and the clinical Juvenile Arthritis Disease Activity Score are composite disease activity scoring systems for juvenile arthritis. Two final trial protocols were established for a future randomised controlled trial.

LIMITATIONS

Fewer clinics were included in this feasibility study than originally planned, limiting the ability to draw strong conclusions about these units to take part in future research.

CONCLUSIONS

A definitive randomised controlled trial is likely to be feasible based on the findings from this study; however, important recommendations should be taken into account when planning such a trial.

FUTURE WORK

This mixed-methods study has laid down the foundations to develop the evidence base in this area and conducting a randomised control trial to compare different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis is likely to be feasible.

STUDY REGISTRATION

Current Controlled Trials ISRCTN16649996.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 36. See the NIHR Journals Library website for further project information.

Plain language summary

ABOUT JUVENILE IDIOPATHIC ARTHRITIS

Juvenile idiopathic arthritis refers to a group of conditions that cause inflammation and damage of the joints, starting in children and young people aged < 16 years. Treatments include anti-inflammatory medicines, disease-modifying/biologic medicines and corticosteroids. Young people often require corticosteroids at the start of their treatment, or in a flare with worsening inflammation, to get their juvenile idiopathic arthritis under control. A short course of corticosteroids can help and can be given by injection into the joint, through a drip into a vein, by injection into the muscle or in the form of tablets or liquid to be taken orally. Although they have been used for decades, there is no research to show the best way(s) of giving corticosteroids.

STUDY AIMS

The study aimed to (1) agree on what corticosteroid treatments to compare in a treatment trial and the best way to measure changes in juvenile idiopathic arthritis to evaluate a quick-acting treatment and (2) find out if there are enough young people with active juvenile idiopathic arthritis in the UK to be included in such a study.

METHODS

Published research on corticosteroids in juvenile idiopathic arthritis was reviewed. Health-care professionals were asked how they choose which corticosteroids to use and which method of administration to use. Interviews were carried out with children and young people and their families to (1) consider the design of a study comparing corticosteroid routes, (2) identify outcomes important to them and (3) determine whether or not they would be willing to take part in a future study. A 3-month feasibility study was carried out to collect details of children and young people with active juvenile idiopathic arthritis before and after corticosteroid treatment to measure improvements in juvenile idiopathic arthritis activity, and to see whether or not a larger study would be possible.

FINDINGS

This study showed that corticosteroids are used in different ways across the UK. The views of children, young people and their families must be taken into account when designing a future study. This study calculated the number of young people who would be needed to take part in the future, showing that it would be possible to do a larger study that compared different corticosteroid treatments, which would help everyone to understand the best way to use corticosteroids.

Full text of this article can be found in Bookshelf.

References

  1. Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996;23:1975–80. [PubMed]
  2. Baszis K, Garbutt J, Toib D, Mao J, King A, White A, French A. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum 2011;63:3163–8. https://doi.org/10.1002/art.30502 doi: 10.1002/art.30502. [DOI] [PubMed]
  3. Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res 2015;67:658–66. https://doi.org/10.1002/acr.22477 doi: 10.1002/acr.22477. [DOI] [PubMed]
  4. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9. https://doi.org/10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R doi: 10.1002/1529-0131(199707)40:7&#x0003c;1202::AID-ART3&#x0003e;3.0.CO;2-R. [DOI] [PubMed]
  5. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66. https://doi.org/10.1002/art.24516 doi: 10.1002/art.24516. [DOI] [PubMed]
  6. McErlane F, Beresford MW, Baildam EM, Thomson W, Hyrich KL. Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. Rheumatology 2013;52:1941–51. https://doi.org/10.1093/rheumatology/ket150 doi: 10.1093/rheumatology/ket150. [DOI] [PubMed]
  7. Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology 2008;47:985–90. https://doi.org/10.1093/rheumatology/ken039 doi: 10.1093/rheumatology/ken039. [DOI] [PMC free article] [PubMed]
  8. Boland EW. The effects of cortisone and adrenocorticotropic hormone (ACTH) on certain rheumatic diseases. Calif Med 1950;72:405–14. [PMC free article] [PubMed]
  9. Davies R, Carrasco R, Foster HE, Baildam EM, Chieng SEA, Davidson JE, et al. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): analysis from the UK Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum 2016;46:190–5. https://doi.org/10.1016/j.semarthrit.2016.06.001 doi: 10.1016/j.semarthrit.2016.06.001. [DOI] [PMC free article] [PubMed]
  10. Wallace CA, Ringold S, Bohnsack J, Spalding SJ, Brunner HI, Milojevic D, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol 2014;41:2459–65. https://doi.org/10.3899/jrheum.140347 doi: 10.3899/jrheum.140347. [DOI] [PubMed]
  11. Petty RE, Laxer RM, Lindsley CB, Wedderburn LR. Textbook of Pediatric Rheumatology 7th edition. Amsterdam: Elsevier; 2016.
  12. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9. https://doi.org/10.1016/S0140-6736(04)16676-2 doi: 10.1016/S0140-6736(04)16676-2. [DOI] [PubMed]
  13. Hetland ML, Stengaard-Pedersen K, Junker P, Østergaard M, Ejbjerg BJ, Jacobsen S, et al. Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69:1789–95. https://doi.org/10.1136/ard.2009.125534 doi: 10.1136/ard.2009.125534. [DOI] [PubMed]
  14. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7. https://doi.org/10.1136/ard.2009.123919 doi: 10.1136/ard.2009.123919. [DOI] [PMC free article] [PubMed]
  15. Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, et al. Physicians’ adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. Ann Rheum Dis 2014;73:788–90. https://doi.org/10.1136/annrheumdis-2013-204271 doi: 10.1136/annrheumdis-2013-204271. [DOI] [PubMed]
  16. Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis 2019;78:51–9. https://doi.org/10.1136/annrheumdis-2018-213902 doi: 10.1136/annrheumdis-2018-213902. [DOI] [PubMed]
  17. Hyrich KL, Lal SD, Foster HE, Thornton J, Adib N, Baildam E, et al. Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology 2010;49:116–22. https://doi.org/10.1093/rheumatology/kep352 doi: 10.1093/rheumatology/kep352. [DOI] [PMC free article] [PubMed]
  18. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL, Intramuscular Methylprednisolone Study Group. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005;64:1288–93. https://doi.org/10.1136/ard.2004.030908 doi: 10.1136/ard.2004.030908. [DOI] [PMC free article] [PubMed]
  19. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, Bohm M, Nieto-Gonzalez JC, Pistorio A, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res 2013;65:1112–20. https://doi.org/10.1002/acr.21947 doi: 10.1002/acr.21947. [DOI] [PubMed]
  20. Tong A, Jones J, Craig JC, Singh-Grewal D. Children’s experiences of living with juvenile idiopathic arthritis: a thematic synthesis of qualitative studies. Arthritis Care Res 2012;64(9):1392–404. https://doi.org/10.1002/acr.21695 doi: 10.1002/acr.21695. [DOI] [PubMed]
  21. Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, et al. Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Ann Rheum Dis 2018;77:319–27. doi: 10.1136/annrheumdis-2017-211904. [DOI] [PubMed]
  22. Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, et al. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology 2016;55:1556–65. https://doi.org/10.1093/rheumatology/kev429 doi: 10.1093/rheumatology/kev429. [DOI] [PMC free article] [PubMed]
  23. Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chédeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res 2010;62:527–36. https://doi.org/10.1002/acr.20044 doi: 10.1002/acr.20044. [DOI] [PubMed]
  24. Shen CC, Yao TC, Yeh KW, Huang JL. Association of disease activity and anti-rheumatic treatment in juvenile idiopathic arthritis with serum lipid profiles: a prospective study. Semin Arthritis Rheum 2013;42:590–6. https://doi.org/10.1016/j.semarthrit.2012.10.002 doi: 10.1016/j.semarthrit.2012.10.002. [DOI] [PubMed]
  25. Gäre BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process. J Rheumatol 1995;22:295–307. [PubMed]
  26. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Rheum Dis Clin North Am 2007;33:441–70, vi. doi: 10.1016/j.rdc.2007.07.006. [DOI] [PubMed]
  27. Cannizzaro E, Schroeder S, Müller LM, Kellenberger CJ, Saurenmann RK. Temporomandibular joint involvement in children with juvenile idiopathic arthritis. J Rheumatol 2011;38:510–15. https://doi.org/10.3899/jrheum.100325 doi: 10.3899/jrheum.100325. [DOI] [PubMed]
  28. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465–82. https://doi.org/10.1002/acr.20460 doi: 10.1002/acr.20460. [DOI] [PMC free article] [PubMed]
  29. Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012;142:176–93. https://doi.org/10.1016/j.clim.2011.10.003 doi: 10.1016/j.clim.2011.10.003. [DOI] [PubMed]
  30. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671–84. https://doi.org/10.1001/jama.294.13.1671 doi: 10.1001/jama.294.13.1671. [DOI] [PubMed]
  31. Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990;8:413–16. [PubMed]
  32. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;1:CD006356. https://doi.org/10.1002/14651858.CD006356 doi: 10.1002/14651858.CD006356. [DOI] [PMC free article] [PubMed]
  33. Picco P, Gattorno M, Buoncompagni A, Pistoia V, Borrone C. 6-methylprednisolone ‘mini-pulses’: a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand J Rheumatol 1996;25:24–7. https://doi.org/10.3109/03009749609082663 doi: 10.3109/03009749609082663. [DOI] [PubMed]
  34. Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology 2004;43:1288–91. https://doi.org/10.1093/rheumatology/keh313 doi: 10.1093/rheumatology/keh313. [DOI] [PubMed]
  35. National Institute for Health and Care Excellence (NICE). Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor. London: NICE; 2010.
  36. National Institute for Health Research. High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma. A Feasibility Study (HiFlo ASA). URL: www.fundingawards.nihr.ac.uk/award/PB-PG-1217-20024 (accessed 15 November 2019).
  37. Hollander JL, Brown EM, Jessar RA, Brown CY. Hydrocortisone and cortisone injected into arthritic joints; comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc 1951;147:1629–35. https://doi.org/10.1001/jama.1951.03670340019005 doi: 10.1001/jama.1951.03670340019005. [DOI] [PubMed]
  38. Bernstein BT, Thompson DM, Singsen BH. Medical therapy of juvenile rheumatoid arthritis. In Miller III JJ, editor. Juvenile Rheumatoid Arthritis. Littleton, MA: PSG Publishing Co; 1979. pp. 197.
  39. Allen RC, Gross KR, Laxer RM, Malleson PN, Beauchamp RD, Petty RE. Intraarticular triamcinolone hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 1986;29:997–1001. https://doi.org/10.1002/art.1780290808 doi: 10.1002/art.1780290808. [DOI] [PubMed]
  40. Cleary AG, Murphy HD, Davidson JE. Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child 2003;88:192–6. https://doi.org/10.1136/adc.88.3.192 doi: 10.1136/adc.88.3.192. [DOI] [PMC free article] [PubMed]
  41. Cunha AL, Miotto E Silva VB, Osaku FM, Niemxeski LB, Furtado RN, Natour J, et al. Intra-articular injection in patients with juvenile idiopathic arthritis: factors associated with a good response. Rev Bras Reumatol Engl Ed 2016;56:490–6. https://doi.org/10.1016/j.rbr.2015.08.010 doi: 10.1016/j.rbr.2015.08.010. [DOI] [PubMed]
  42. Gotte AC. Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: safety, efficacy, and features affecting outcome. A comprehensive review of the literature. Open Access Rheumatol 2009;1:37–49. https://doi.org/10.2147/OARRR.S5103 doi: 10.2147/OARRR.S5103. [DOI] [PMC free article] [PubMed]
  43. Davoudi A, Khaki H, Mohammadi I, Daneshmand M, Tamizifar A, Bigdelou M, Ansaripoor F. Is arthrocentesis of temporomandibular joint with corticosteroids beneficial? A systematic review. Med Oral Patol Oral Cir Bucal 2018;23:e367–75. https://doi.org/10.4317/medoral.21925 doi: 10.4317/medoral.21925. [DOI] [PMC free article] [PubMed]
  44. Ravelli A, Davì S, Bracciolini G, Pistorio A, Consolaro A, van Dijkhuizen EHP, et al. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet 2017;389:909–16. https://doi.org/10.1016/S0140-6736(17)30065-X doi: 10.1016/S0140-6736(17)30065-X. [DOI] [PubMed]
  45. Bird HA, Ring EF, Bacon PA. A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis. Ann Rheum Dis 1979;38:36–9. https://doi.org/10.1136/ard.38.1.36 doi: 10.1136/ard.38.1.36. [DOI] [PMC free article] [PubMed]
  46. Balogh Z, Ruzsonyi E. Triamcinolone hexacetonide versus betamethasone. A double-blind comparative study of the long-term effects of intra-articular steroids in patients with juvenile chronic arthritis. Scand J Rheumatol Suppl 1987;67:80–2. https://doi.org/10.3109/03009748809105305 doi: 10.3109/03009748809105305. [DOI] [PubMed]
  47. Honkanen VE, Rautonen JK, Pelkonen PM. Intra-articular glucocorticoids in early juvenile chronic arthritis. Acta Paediatr 1993;82:1072–4. https://doi.org/10.1111/j.1651-2227.1993.tb12815.x doi: 10.1111/j.1651-2227.1993.tb12815.x. [DOI] [PubMed]
  48. Zulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology 2003;42:1254–9. https://doi.org/10.1093/rheumatology/keg358 doi: 10.1093/rheumatology/keg358. [DOI] [PubMed]
  49. Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004;31:2507–12. [PubMed]
  50. Bagri NK, Tripathy SK. Intra-articular corticosteroid administration. Indian Pediatr 2018;55:612. https://doi.org/10.1007/s13312-018-1310-8 doi: 10.1007/s13312-018-1310-8. [DOI] [PubMed]
  51. Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther 1986;39:313–17. https://doi.org/10.1038/clpt.1986.45 doi: 10.1038/clpt.1986.45. [DOI] [PubMed]
  52. Southwood TR. ABC of rheumatology. Arthritis in children. BMJ 1995;310:728–32. https://doi.org/10.1136/bmj.310.6981.728 doi: 10.1136/bmj.310.6981.728. [DOI] [PMC free article] [PubMed]
  53. Ravelli A, Lattanzi B, Consolaro A, Martini A. Glucocorticoids in paediatric rheumatology. Clin Exp Rheumatol 2011;29(Suppl. 5):148–52. [PubMed]
  54. Michels H. What is low-dose corticosteroid therapy in juvenile idiopathic arthritis? A worldwide, questionnaire-based survey. Z Rheumatol 2000;59:127–30. https://doi.org/10.1007/PL00022855 doi: 10.1007/PL00022855. [DOI] [PubMed]
  55. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854–60. https://doi.org/10.1136/annrheumdis-2014-205372 doi: 10.1136/annrheumdis-2014-205372. [DOI] [PubMed]
  56. Lord M, Allaoua M, Ratib O. Positron emission tomography findings in systemic juvenile idiopathic arthritis. Rheumatology 2011;50:1177. https://doi.org/10.1093/rheumatology/ker136 doi: 10.1093/rheumatology/ker136. [DOI] [PubMed]
  57. Mellos A, Mauro A, Granato C, Gicchino MF, Perrone L, Olivieri AN. Refractory systemic juvenile idiopathic arthritis complicated by coxarthrosis. Pediatric Rheumatol 2014;12:P232. https://doi.org/10.1186/1546-0096-12-S1-P232 doi: 10.1186/1546-0096-12-S1-P232. [DOI]
  58. Weiss JE, DeWitt EMM, Beukelman T, Schanbrg LE, Schneider R, Kimura Y. Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists. Proceedings of the ACR/ARHP Annual Meeting, 9–12 November 2012, Washington DC, USA.
  59. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol 2014;41:1163–70. https://doi.org/10.3899/jrheum.131503 doi: 10.3899/jrheum.131503. [DOI] [PubMed]
  60. Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009;76:383–8. https://doi.org/10.1016/j.jbspin.2008.10.015 doi: 10.1016/j.jbspin.2008.10.015. [DOI] [PubMed]
  61. Nouar D, Hoarau C, Uettwiller F, Le Lez ML. Non-infectious pediatric uveitis in a single french tertiary center. Pediatric Rheumatol 2014;12:P233. https://doi.org/10.1186/1546-0096-12-S1-P233 doi: 10.1186/1546-0096-12-S1-P233. [DOI]
  62. Verstappen SM, McCoy MJ, Roberts C, Dale NE, Hassell AB, Symmons DP, STIVEA investigators. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 2010;69:503–9. https://doi.org/10.1136/ard.2009.119149 doi: 10.1136/ard.2009.119149. [DOI] [PubMed]
  63. Shiff NJ, Brant R, Guzman J, Cabral DA, Huber AM, Miettunen P, et al. Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases. Arthritis Care Res 2013;65:113–21. https://doi.org/10.1002/acr.21785 doi: 10.1002/acr.21785. [DOI] [PMC free article] [PubMed]
  64. Huppertz HI, Pfüller H. Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. J Rheumatol 1997;24:1833–7. [PubMed]
  65. Goldzweig O, Carrasco R, Hashkes PJ. Systemic adverse events following intraarticular corticosteroid injections for the treatment of juvenile idiopathic arthritis: two patients with dermatologic adverse events and review of the literature. Semin Arthritis Rheum 2013;43:71–6. https://doi.org/10.1016/j.semarthrit.2012.12.006 doi: 10.1016/j.semarthrit.2012.12.006. [DOI] [PubMed]
  66. Valta H, Lahdenne P, Jalanko H, Aalto K, Mäkitie O. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis. J Rheumatol 2007;34:831–6. [PubMed]
  67. Esbjörnsson AC, Iversen MD, André M, Hagelberg S, Schwartz MH, Broström EW. Effect of intraarticular corticosteroid foot injections on walking function in children with juvenile idiopathic arthritis. Arthritis Care Res 2015;67:1693–701. https://doi.org/10.1002/acr.22624 doi: 10.1002/acr.22624. [DOI] [PubMed]
  68. Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology 2016;55:840–7. https://doi.org/10.1093/rheumatology/kev434 doi: 10.1093/rheumatology/kev434. [DOI] [PMC free article] [PubMed]
  69. Sherratt FC, Roper L, Stones SR, McErlane F, Peak M, Beresford MW, et al. Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials. Pediatr Rheumatol Online J 2018;16:76. https://doi.org/10.1186/s12969-018-0293-2 doi: 10.1186/s12969-018-0293-2. [DOI] [PMC free article] [PubMed]
  70. Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum 2010;62:3131–9. https://doi.org/10.1002/art.27670 doi: 10.1002/art.27670. [DOI] [PubMed]
  71. Al-Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet 2014;383:176–85. https://doi.org/10.1016/S0140-6736(13)62297-7 doi: 10.1016/S0140-6736(13)62297-7. [DOI] [PMC free article] [PubMed]
  72. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open 2012;2:e000496. https://doi.org/10.1136/bmjopen-2011-000496 doi: 10.1136/bmjopen-2011-000496. [DOI] [PMC free article] [PubMed]
  73. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials 2013;14:166. https://doi.org/10.1186/1745-6215-14-166 doi: 10.1186/1745-6215-14-166. [DOI] [PMC free article] [PubMed]
  74. Tishler CL, Reiss NS. Pediatric drug-trial recruitment: enticement without coercion. Pediatrics 2011;127:949–54. https://doi.org/10.1542/peds.2010-2585 doi: 10.1542/peds.2010-2585. [DOI] [PubMed]
  75. Berard RA, Laxer RM. Learning the hard way: clinical trials in juvenile idiopathic arthritis. Ann Rheum Dis 2018;77:1–2. https://doi.org/10.1136/annrheumdis-2017-211108 doi: 10.1136/annrheumdis-2017-211108. [DOI] [PubMed]
  76. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet 2004;364:803–11. https://doi.org/10.1016/S0140-6736(04)16942-0 doi: 10.1016/S0140-6736(04)16942-0. [DOI] [PubMed]
  77. Smyth RL, Weindling AM. Research in children: ethical and scientific aspects. Lancet 1999;354(Suppl. 2):21–4. https://doi.org/10.1016/S0140-6736(99)90253-2 doi: 10.1016/S0140-6736(99)90253-2. [DOI] [PubMed]
  78. Balevic SJ, Becker ML, Cohen-Wolkowiez M, Schanberg LE. Clinical trial design in juvenile idiopathic arthritis. Paediatr Drugs 2017;19:379–89. https://doi.org/10.1007/s40272-017-0244-2 doi: 10.1007/s40272-017-0244-2. [DOI] [PMC free article] [PubMed]
  79. Douglas SL. A consumer perspective on embedding research in paediatric rheumatology. Rheumatology 2014;53:1915–16. https://doi.org/10.1093/rheumatology/ket461 doi: 10.1093/rheumatology/ket461. [DOI] [PubMed]
  80. O’Cathain A, Hoddinott P, Lewin S, Thomas KJ, Young B, Adamson J, et al. Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: guidance for researchers. Pilot Feasibility Stud 2015;1:32. https://doi.org/10.1186/s40814-015-0026-y doi: 10.1186/s40814-015-0026-y. [DOI] [PMC free article] [PubMed]
  81. O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Goode J, Hewison J. Maximising the value of combining qualitative research and randomised controlled trials in health research: the QUAlitative Research in Trials (QUART) study – a mixed methods study. Health Technol Assess 2014;18(38). https://doi.org/10.3310/hta18380 doi: 10.3310/hta18380. [DOI] [PMC free article] [PubMed]
  82. Beadle-Brown J, Ryan S, Windle K, Holder J, Turnpenny A, Smith N, et al. Engagement of People with Long Term Conditions in Health and Social Care Research: Barriers and Facilitators to Capturing the Views of Seldom-Heard Populations. Canterbury: Quality and Outcomes of Person-Centred Care Policy Research Unit, University of Kent; 2012.
  83. Richie J, Lewis J. Qualitative Research Practice: A Guide for Social Science Students and Researchers. London: SAGE Publications Ltd; 2003.
  84. Lees A, Payler J, Ballinger C, Lawrence P, Faust SN, Meads G. Positioning children’s voice in clinical trials research: a new model for planning, collaboration, and reflection. Qual Health Res 2017;27:2162–76. https://doi.org/10.1177/1049732317726760 doi: 10.1177/1049732317726760. [DOI] [PubMed]
  85. Barriball KL, While A. Collecting data using a semi-structured interview: a discussion paper. J Adv Nurs 1994;19:328–35. https://doi.org/10.1111/j.1365-2648.1994.tb01088.x doi: 10.1111/j.1365-2648.1994.tb01088.x. [DOI] [PubMed]
  86. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2. [PubMed]
  87. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991–4. [PubMed]
  88. Ness LR. Are we there yet? Data saturation in qualitative research. Qualitative Report 2015;20:1408–16.
  89. Marti P, Molinari L, Bolt IB, Seger R, Saurenmann RK. Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr 2008;167:425–30. https://doi.org/10.1007/s00431-007-0525-9 doi: 10.1007/s00431-007-0525-9. [DOI] [PubMed]
  90. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013;13:117. https://doi.org/10.1186/1471-2288-13-117 doi: 10.1186/1471-2288-13-117. [DOI] [PMC free article] [PubMed]
  91. Morrow SL. Quality and trustworthiness in qualitative research in counseling psychology. J Couns Psychol 2005;52:250. https://doi.org/10.1037/0022-0167.52.2.250 doi: 10.1037/0022-0167.52.2.250. [DOI]
  92. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 2014;89:1245–51. https://doi.org/10.1097/ACM.0000000000000388 doi: 10.1097/ACM.0000000000000388. [DOI] [PubMed]
  93. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19:349–57. https://doi.org/10.1093/intqhc/mzm042 doi: 10.1093/intqhc/mzm042. [DOI] [PubMed]
  94. Ministry of Housing, Communities and Local Government. English Indices of Deprivation 2015: Research Report. London: Ministry of Housing, Communities and Local Government; 2015.
  95. Nuffield Council on Bioethics. Children and Clinical Research: Ethical Issues. London: Nuffield Council on Bioethics; 2015.
  96. Shaw C, Brady LM, Davey C. Guidelines for Research with Children and Young People. London: National Children’s Bureau Research Centre; 2011.
  97. Boland L, McIsaac DI, Lawson ML. Barriers to and facilitators of implementing shared decision making and decision support in a paediatric hospital: a descriptive study. Paediatr Child Health 2016;21:e17–21. https://doi.org/10.1093/pch/21.3.e17 doi: 10.1093/pch/21.3.e17. [DOI] [PMC free article] [PubMed]
  98. Zwaanswijk M, Tates K, van Dulmen S, Hoogerbrugge PM, Kamps WA, Beishuizen A, Bensing JM. Communicating with child patients in pediatric oncology consultations: a vignette study on child patients’, parents’, and survivors’ communication preferences. Psycho-Oncology 2011;20:269–77. https://doi.org/10.1002/pon.1721 doi: 10.1002/pon.1721. [DOI] [PubMed]
  99. Madden L, Shilling V, Woolfall K, Sowden E, Smyth RL, Williamson PR, et al. Questioning assent: how are children’s views included as families make decisions about clinical trials? Child Care Health Dev 2016;42:900–8. https://doi.org/10.1111/cch.12347 doi: 10.1111/cch.12347. [DOI] [PMC free article] [PubMed]
  100. Young B, Dixon-Woods M, Windridge KC, Heney D. Managing communication with young people who have a potentially life threatening chronic illness: qualitative study of patients and parents. BMJ 2003;326:305. https://doi.org/10.1136/bmj.326.7384.305 doi: 10.1136/bmj.326.7384.305. [DOI] [PMC free article] [PubMed]
  101. Williams C. Alert assistants in managing chronic illness: the case of mothers and teenage sons. Sociol Health Illn 2000;22:254–72. https://doi.org/10.1111/1467-9566.00202 doi: 10.1111/1467-9566.00202. [DOI]
  102. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006;7:141–8. https://doi.org/10.1016/S1470-2045(06)70576-9 doi: 10.1016/S1470-2045(06)70576-9. [DOI] [PubMed]
  103. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999;52:1143–56. https://doi.org/10.1016/S0895-4356(99)00141-9 doi: 10.1016/S0895-4356(99)00141-9. [DOI] [PubMed]
  104. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al. Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA 2005;293:1089–99. https://doi.org/10.1001/jama.293.9.1089 doi: 10.1001/jama.293.9.1089. [DOI] [PubMed]
  105. Elliott D, Husbands S, Hamdy FC, Holmberg L, Donovan JL. Understanding and improving recruitment to randomised controlled trials: qualitative research approaches. Eur Urol 2017;72:789–98. https://doi.org/10.1016/j.eururo.2017.04.036 doi: 10.1016/j.eururo.2017.04.036. [DOI] [PubMed]
  106. Shilling V, Williamson PR, Hickey H, Sowden E, Beresford MW, Smyth RL, et al. Communication about children’s clinical trials as observed and experienced: qualitative study of parents and practitioners. PLOS ONE 2011;6:e21604. https://doi.org/10.1371/journal.pone.0021604 doi: 10.1371/journal.pone.0021604. [DOI] [PMC free article] [PubMed]
  107. Caldwell PH, Butow PN, Craig JC. Pediatricians’ attitudes toward randomized controlled trials involving children. J Pediatr 2002;141:798–803. https://doi.org/10.1067/mpd.2002.129173 doi: 10.1067/mpd.2002.129173. [DOI] [PubMed]
  108. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999;3(20). https://doi.org/10.3310/hta3200 doi: 10.3310/hta3200. [DOI] [PubMed]
  109. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: version 1.0. Trials 2017;18:280. https://doi.org/10.1186/s13063-017-1978-4 doi: 10.1186/s13063-017-1978-4. [DOI] [PMC free article] [PubMed]
  110. Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, et al. Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: report from a special interest group at OMERACT 2016. J Rheumatol 2017;44:1884–8. https://doi.org/10.3899/jrheum.161389 doi: 10.3899/jrheum.161389. [DOI] [PMC free article] [PubMed]
  111. Alderson P. Competent children? Minors’ consent to health care treatment and research. Soc Sci Med 2007;65:2272–83. https://doi.org/10.1016/j.socscimed.2007.08.005 doi: 10.1016/j.socscimed.2007.08.005. [DOI] [PubMed]
  112. Morain SR, Whicher DM, Kass NE, Faden RR. Deliberative engagement methods for patient-centered outcomes research. Patient 2017;10:545–52. https://doi.org/10.1007/s40271-017-0238-8 doi: 10.1007/s40271-017-0238-8. [DOI] [PubMed]
  113. Akobeng AK. Understanding randomised controlled trials. Arch Dis Child 2005;90:840–4. https://doi.org/10.1136/adc.2004.058222 doi: 10.1136/adc.2004.058222. [DOI] [PMC free article] [PubMed]
  114. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline: Statistical Principles for Clinical Trials. ICH; 1998.
  115. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. Trials 2012;13:132. https://doi.org/10.1186/1745-6215-13-132 doi: 10.1186/1745-6215-13-132. [DOI] [PMC free article] [PubMed]
  116. Fergusson D, Monfaredi Z, Pussegoda K, Garritty C, Lyddiatt A, Shea B, et al. The prevalence of patient engagement in published trials: a systematic review. Res Involv Engagem 2018;4:17. https://doi.org/10.1186/s40900-018-0099-x doi: 10.1186/s40900-018-0099-x. [DOI] [PMC free article] [PubMed]
  117. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376–80. https://doi.org/10.1136/bmj.311.7001.376 doi: 10.1136/bmj.311.7001.376. [DOI] [PMC free article] [PubMed]
  118. Allen J, Dyas J, Jones M. Building consensus in health care: a guide to using the nominal group technique. Br J Community Nurs 2004;9:110–14. https://doi.org/10.12968/bjcn.2004.9.3.12432 doi: 10.12968/bjcn.2004.9.3.12432. [DOI] [PubMed]
  119. Delp P, Thesen A, Motiwalla J, Seshardi N. Nominal Group Technique. Systems Tools for Project Planning. Bloomington, IN: International Development Institute, University of Indiana; 1977. pp. 14–18.
  120. Products: ResponseCard RF Accessibility. URL: www.turningtechnologies.co.uk/response-options (accessed 15 November 2019).
  121. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395–400. https://doi.org/10.1016/j.jclinepi.2010.09.012 doi: 10.1016/j.jclinepi.2010.09.012. [DOI] [PubMed]
  122. Cartwright J, Kabir T, Simons L. Budgeting for Involvement. London: INVOLVE; 2013.
  123. McErlane F, Foster HE, Armitt G, Bailey K, Cobb J, Davidson JE, et al. Development of a national audit tool for juvenile idiopathic arthritis: a BSPAR project funded by the Health Care Quality Improvement Partnership. Rheumatology 2018;57:140–51. https://doi.org/10.1093/rheumatology/kex322 doi: 10.1093/rheumatology/kex322. [DOI] [PMC free article] [PubMed]
  124. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290–4. [PubMed]
  125. Sherratt F, Roper L, Baildam E, Peak M, McErlane F, Stones S, et al. Family Perspectives on the Feasibility of a Corticosteroid Induction Regimen Randomised Controlled Trial in Juvenile Idiopathic Arthritis: Results of a Qualitative Study. Proceedings of the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials, 7–10 May 2017, Liverpool, UK. pp. 146.
  126. Gorst SL, Gargon E, Clarke M, Blazeby JM, Altman DG, Williamson PR. Choosing important health outcomes for comparative effectiveness research: an updated review and user survey. PLOS ONE 2016;11:e0146444. https://doi.org/10.1371/journal.pone.0146444 doi: 10.1371/journal.pone.0146444. [DOI] [PMC free article] [PubMed]
  127. Gal T, Duramy B. International Perspectives and Empirical Findings on Child Participation: From Social Exclusion to Child-Inclusive Policies. Oxford: Oxford University Press; 2015. https://doi.org/10.1093/acprof:oso/9780199366989.001.0001 doi: 10.1093/acprof:oso/9780199366989.001.0001. [DOI]
  128. Roberts H. Listening to Children: And Hearing Them. In Christensen P, James A, editors. Research with Children. London: Routledge; 2017. pp. 154–71.
  129. Liabo K, Boddy K, Burchmore H, Cockcroft E, Britten N. Clarifying the roles of patients in research. BMJ 2018;361:k1463. https://doi.org/10.1136/bmj.k1463 doi: 10.1136/bmj.k1463. [DOI] [PubMed]
  130. Freemantle N, Calvert MJ. Interpreting composite outcomes in trials. BMJ 2010;341:c3529. https://doi.org/10.1136/bmj.c3529 doi: 10.1136/bmj.c3529. [DOI] [PubMed]
  131. Consolaro A, Giancane G, Schiappapietra B, Davì S, Calandra S, Lanni S, Ravelli A. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2016;14:23. https://doi.org/10.1186/s12969-016-0085-5 doi: 10.1186/s12969-016-0085-5. [DOI] [PMC free article] [PubMed]
  132. Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis 2012;71:1122–7. https://doi.org/10.1136/annrheumdis-2011-200237 doi: 10.1136/annrheumdis-2011-200237. [DOI] [PubMed]
  133. McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 2013;72:1983–8. https://doi.org/10.1136/annrheumdis-2012-202031 doi: 10.1136/annrheumdis-2012-202031. [DOI] [PMC free article] [PubMed]
  134. Yardley L, Spring BJ, Riper H, Morrison LG, Crane DH, Curtis K, et al. Understanding and promoting effective engagement with digital behavior change interventions. Am J Prev Med 2016;51:833–42. https://doi.org/10.1016/j.amepre.2016.06.015 doi: 10.1016/j.amepre.2016.06.015. [DOI] [PubMed]
  135. Sommer C, Zuccolin D, Arnera V, Schmitz N, Adolfsson P, Colombo N, et al. Building clinical trials around patients: evaluation and comparison of decentralized and conventional site models in patients with low back pain. Contemp Clin Trials Commun 2018;11:120–6. https://doi.org/10.1016/j.conctc.2018.06.008 doi: 10.1016/j.conctc.2018.06.008. [DOI] [PMC free article] [PubMed]
  136. Bergold J, Thomas S. Participatory research methods: a methodological approach in motion. Historical Social Research/Historische Sozialforschung 2012;13:191–222.
  137. Curran JA, Bishop A, Chorney J, MacEachern L, Mackay R. Partnering with parents to advance child health research. Healthc Manage Forum 2018;31:45–50. https://doi.org/10.1177/0840470417744568 doi: 10.1177/0840470417744568. [DOI] [PubMed]
  138. Sheridan R, Martin-Kerry J, Watt I, Higgins S, Stones SR, Taylor DH, et al. User testing digital, multimedia information to inform children, adolescents and their parents about healthcare trials. J Child Health Care 2019;23:468–82. https://doi.org/10.1177/1367493518807325 doi: 10.1177/1367493518807325. [DOI] [PubMed]
  139. Cantrill JA, Sibbald B, Buetow S. The Delphi and nominal group techniques in health services research. Int J Pharm Pract 1996;4:67–74. https://doi.org/10.1111/j.2042-7174.1996.tb00844.x doi: 10.1111/j.2042-7174.1996.tb00844.x. [DOI]
  140. Wainwright D, Boichat C, McCracken LM. Using the nominal group technique to engage people with chronic pain in health service development. Int J Health Plann Manage 2014;29:52–69. https://doi.org/10.1002/hpm.2163 doi: 10.1002/hpm.2163. [DOI] [PubMed]
  141. McErlane F, Armitt G, Cobb J, Bailey K, Cleary G, Douglas S, et al. CAPTURE-JIA: a consensus-derived core dataset to improve clinical care for children and young people with juvenile idiopathic arthritis. Rheumatology 2020;59:137–45. https://doi.org/10.1093/rheumatology/kez214 doi: 10.1093/rheumatology/kez214. [DOI] [PMC free article] [PubMed]
  142. Jaki T, Magirr D. Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. Stat Med 2013;32:1150–63. https://doi.org/10.1002/sim.5669 doi: 10.1002/sim.5669. [DOI] [PubMed]
  143. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika 2012;99:494–501. https://doi.org/10.1093/biomet/ass002 doi: 10.1093/biomet/ass002. [DOI]
  144. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549–56. https://doi.org/10.2307/2530245 doi: 10.2307/2530245. [DOI] [PubMed]

RESOURCES